Mix-and-match vaccines highly effective against COVID-19: Lancet study Since the use of AstraZeneca#39;s vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose.